J&J goes block­buster hunt­ing (again) with $245M cash up­front for next-gen CAR-T

J&J is work­ing on cre­at­ing its next Leg­end. On­ly this time, it’s mov­ing right in­to the dri­ver’s seat in­stead of tak­ing the co-pi­lot role.

This morn­ing the phar­ma gi­ant put out word that it’s fork­ing over $245 mil­lion in a hefty cash up­front to land glob­al de­vel­op­ment and com­mer­cial­iza­tion rights to two ear­ly-stage, au­tol­o­gous CAR-T ther­a­py pro­grams from a US/Chi­na play­er — CB­MG — that has a track record of al­ly­ing it­self with the biggest names in the de­vel­op­ment world. And they’re go­ing right af­ter B-cell ma­lig­nan­cies.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.